Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEmmerson Plc Regulatory News (EML)

Share Price Information for Emmerson Plc (EML)

Share Price is delayed by 15 minutes
Get Live Data
2.10    0.00 (0.00%)
Bid:
2.00
Ask:
2.20
Spread: 0.20 (10.00%)
Market Cap: £28.06m
EML Live PriceLast checked at - London Stock Exchange

Intraday Emmerson Plc Share Chart

ESIA Process, Board Changes, and Cash Management

28 Oct 2024 07:00

RNS Number : 7737J
Emmerson PLC
28 October 2024
Ā 

Emmerson PLC / Ticker: EML / Index: AIM / Sector: Mining

28 October 2024

Emmerson PLC

("Emmerson" or the "Company")

Ā 

ESIA Approval Process, Changes to the Board and Cash Management Initiatives

Ā 

Emmerson, the Moroccan focused potash development company, provides an update on the ESIA approval process, changes to its Board and various cash management initiatives.

Ā 

ESIA Approval

Ā 

As previously announced, the Company was made aware of an unfavourable recommendation regarding its ESIA application.

Ā 

Following discussions with the Company's Moroccan advisors, the Company filed an appeal with the Wali of Rabat-SalƩ-KƩnitra region (which encompasses the province of Khemisset) with respect to the unfavourable recommendation from the Commission RƩgionale UnifiƩe de l'Investissement ("CRUI").

Ā 

The Centre RƩgional d'Investissement of the region Rabat-SalƩ-KƩnitra ("CRI") has subsequently responded that the CRUI does not have the ability to examine the ESIA submission again and it did not provide any indication of further avenues of appeal to the Company.

Ā 

Emmerson continues to examine its options with respect to the approvals process and will update the market shortly on its next steps.

Ā 

Changes to the Board

Ā 

James Kelly (Non-Executive Chairman) and Rupert Joy (Non-Executive Director) will both step down from the Board of Directors, with immediate effect.

Hayden Locke will assume the role of Chairman to support management during the next phase of work.

Ā 

Cash Management Initiatives

Ā 

The permitting delays have put Emmerson's balance sheet under pressure and limited its future financing options. As a result, the Company has implemented a comprehensive review to significantly reduce its cash burn rate while it assesses its strategic and appeal options with respect to the recent unfavourable recommendation.

Ā 

In addition to the streamlining of the Board, from 1 November 2024, the two remaining non-executive directors (Mr Locke and Mr Wrixon) will suspend taking their cash fees and will, instead, take fees in the form of shares to continue to align them with the interests of other shareholders.

Ā 

Graham Clarke, the Managing Director and CEO, will reduce his base cash compensation by 40%, which will be reviewed on an ongoing quarterly basis with respect to the Company's financial position and ongoing prospects. Mr Clarke will also take a portion of the reduction in shares.

The majority of the remaining ongoing costs within the business, with the exception of core administrative and regulatory functions, are being reviewed and will be significantly reduced. Unfortunately, this will mean, for the time being, that virtually no further progress can be made on the various value-adding project development workstreams underway.

Ā 

Hayden Locke, in-coming Chairman of Emmerson, commented:

Ā 

"I would like to thank both James and Rupert for their wise counsel and commitment to Emmerson during what has been a very challenging period for the Company. Both are disappointed with the outcome and are reticent to leave at this important juncture, but they also recognise a restructuring is necessary to preserve optionality for the Company, and any remaining potential for value for our stakeholders.

Ā 

"Thank you to Graham for his continued commitment to the Company, taking a significant reduction in remuneration while continuing to work incredibly hard as we assess our options. Many investors mistake silence for lack of activity but, in our current situation, it is difficult to make appropriate and conclusive statements when we have no clarity on our position, without prejudicing our potential future options.

Ā 

"Graham, Rob and I are working hard to assess our next steps, and I look forward to updating the market when our path becomes clear.

Ā 

"We thank our remaining shareholders for their patience."

Ā 

Market Abuse Regulation (MAR) Disclosure

This announcement contains inside information for the purposes of theĀ UKĀ Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

Ā 

**ENDS**

Ā 

For further information, please visitĀ www.emmersonplc.com, follow us on Twitter (@emmerson_plc), or contact:

Ā 

Emmerson PLC

Graham Clarke / Charles Vaughan

Ā 

Ā 

+44 (0) 207 138 3204

Panmure Liberum Limited (Nominated Advisor and Joint Broker)

Scott Mathieson / Matthew Hogg

Ā 

Ā 

+44 (0)20 3100 2000

Shard Capital (Joint Broker)

Damon Heath / Isabella Pierre

Ā 

+44 (0)20 7186 9927

Ā 

BlytheRay (Financial PR and IR)

Tim Blythe / Megan Ray / Said Izagaren

Ā 

+44 (0) 207 138 3204

Ā 

Notes to Editors

Emmerson is focused on advancing the Khemisset project ("Khemisset" or the "Project") in Morocco into a low cost, high margin supplier of potash, and the first primary producer on the African continent. With an initial 19-year life of mine, the development of Khemisset is expected to deliver long-term investment and financial contributions to Morocco including the creation of permanent employment, taxation, and a plethora of ancillary benefits. As a UK-Moroccan partnership, the Company is committed to bringing in significant international investment over the life of the mine.

Ā 

Morocco is widely recognised as one of the leading phosphate producers globally, ranking third in the world in terms of tonnes produced annually, and the development of this mine is set to consolidate its position as the most important fertiliser producer in Africa. The Project has a large JORC Resource Estimate (2012) of 537Mt @ 9.24% K2O, with significant exploration potential, and is perfectly located to support the expected growth of African fertiliser consumption whilst also being located on the doorstep of European markets. The need to feed the world's rapidly increasing population is driving demand for potash and Khemisset is well placed to benefit from the opportunities this presents. The Feasibility Study released in June 2020 indicated the Project has the potential to be among the lowest capital cost development stage potash projects in the world and also, as a result of its location, one of the highest margin projects. This delivered outstanding economics, including a post-tax NPV8 of approximately US$1.4 billion using industry expert Argus' price forecasts.

Ā 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Ā 
END
Ā 
Ā 
MSCMRBTTMTTTTAI
Date   Source Headline
30th Mar 20267:00 amRNSArbitration Memorial Submission
24th Mar 20267:00 amRNSResult of WRAP Retail Offer
20th Mar 20267:31 amRNSWRAP Retail Offer for up to £100,000
20th Mar 20267:30 amRNSResult of Placing and Subscription
20th Mar 20267:00 amRNSProposed Placing and Subscription
22nd Jan 20267:00 amRNSArbitration Update
26th Nov 20257:00 amRNSAppointment of Joint Broker
30th Sep 20257:00 amRNSInterim Results
24th Jul 202512:31 pmRNSResult of Annual General Meeting
1st Jul 20257:00 amRNSNotice of AGM
30th Jun 20253:36 pmRNS2024 Financial Results
1st May 20258:10 amRNSRequest for Arbitration
17th Mar 20257:00 amRNSLitigation Funding Update
13th Jan 20253:03 pmRNSAdditional Issuance of Shares and Rights
2nd Jan 20257:00 amRNSLitigation Funding Secured
12th Dec 20247:00 amRNSAdditional Issuance of Shares and Rights
6th Dec 20247:01 amRNSFundraising of £0.85 million
1st Nov 20247:00 amRNSNotice of dispute with Moroccan Government
28th Oct 20247:00 amRNSESIA Process, Board Changes, and Cash Management
14th Oct 20247:00 amRNSESIA Update
27th Sep 20247:00 amRNSInterim Results and Q3 Update
5th Jul 20247:00 amRNSQ2 Update
1st Jul 20247:00 amRNSChange of Nominated Advisor and Joint Broker
26th Jun 202411:33 amRNSResult of Annual General Meeting
31st May 202410:56 amRNSGrant of Share Options and PDMR dealing
31st May 20247:00 amRNSNotice of AGM and Posting of Annual Report
24th May 20247:00 amRNS2023 Financial Results
22nd Apr 202411:47 amRNSTR-1: Notification of major holdings
8th Apr 20244:45 pmRNSResults of Oversubscribed REX Retail Offer
8th Apr 20247:01 amRNSREX Retail Offer
8th Apr 20247:00 amRNSQ1 Update, Equity Placing and Retail Offer
11th Mar 20247:00 amRNSCommittee Upholds Environmental Approval Referral
1st Feb 20247:00 amRNSScoping Study on Breakthrough New Processing Route
8th Jan 20247:00 amRNSQ4 Update
21st Dec 20237:00 amRNSExtension of Mandated Lead Arrangers
26th Sep 20237:00 amRNSInterim Results for the six months to 30 June 2023
21st Sep 20237:00 amRNSQ3 2023 and Financing update
11th Sep 202311:38 amRNSMorocco Statement
11th Jul 202311:57 amRNSDirector/PDMR Shareholding
10th Jul 20234:30 pmRNSDirector/PDMR Shareholding
6th Jul 20232:49 pmRNSDirector/PDMR Shareholding
6th Jul 20237:00 amRNSQ2 Update
6th Jun 20237:00 amRNSExercise & Allotment of Shares
31st May 202312:01 pmRNSResult of AGM
5th May 20237:00 amRNSNotice of AGM and Posting of Annual Report
13th Apr 20237:00 amRNS2022 Financial Results and Q1 Update
14th Feb 20237:00 amRNSMandated Lead Arrangers Appointed for Financing
9th Jan 20237:00 amRNSQ4 Update
3rd Jan 20237:00 amRNSAppointment of Liberum as Nominated Advisor
21st Nov 20227:00 amRNSPotash and Salt Offtake MOUs

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.